LAS VEGAS, Feb. 17, 2020 /PRNewswire/ -- Western
Veterinary Conference (WVC) booth #1118 -- Antech Diagnostics,
part of Mars Petcare, announced today the addition of Antech SDMA™
(symmetric dimethylarginine) to its feline renal health portfolio.
A renal biomarker for early diagnosis, staging and monitoring of
chronic kidney disease (CKD), Antech SDMA complements
RenalTech™, which can predict CKD onset two years
before disease occurs. The expanded renal health portfolio
gives veterinarians the first complete solution for feline CKD
prediction, early diagnosis, monitoring and staging, ensuring they
can support the best possible outlook for cats facing disease.
Antech SDMA for cats and dogs will be available in late
spring.
Antech's complete feline renal health portfolio allows
veterinarians to provide early, precision care for CKD that matches
the unique health status of each cat, supporting optimal health as
well as continued pet owner confidence and care plan compliance.
Using RenalTech, named Best New Companion Animal Product of 2019,
veterinarians can predict CKD two years before it occurs with
greater than 95% accuracy. The unique ability to predict disease
allows proactive personalized care plans designed to slow disease
onset and progression. Antech SDMA allows veterinarians to identify
CKD early, tailoring care plans to meet the individual needs of
each cat. Once disease is underway, Antech SDMA helps veterinarians
monitor and stage disease according to updated International Renal
Interest Society (IRIS) guidelines, once again adjusting care plans
to specific disease progress.
"The outlook for CKD in cats is absolutely changing," said
Jennifer Ogeer, BSc., DVM, MSc.,
MBA, MA, VP Medical Affairs & Commercial Marketing. "The
opportunity for disease prediction, early diagnosis, staging and
disease monitoring in one complete solution gives us an
unprecedented opportunity to create, tailor and revise highly
personalized care plans to ensure we're following IRIS guidelines,
recommending exactly what a cat needs, when they need it. Our new
renal health portfolio is evidence of our commitment not only to
delivering the most innovative diagnostics in veterinary medicine
but also creating the comprehensive toolkits that, in this
instance, allow veterinarians to use available biomarkers exactly
as guidelines recommend to set new standards of care in veterinary
medicine."
CKD affects 30-40 percent of cats over the age of 10. Early
management may slow the progression of disease. However,
traditional diagnostics find disease only once it's underway and
significant, irreversible kidney damage has already occurred.
RenalTech creates an opportunity for early care strategies to work
by predicting disease before it begins. By analyzing common feline
health parameters—all obtained from a minimum database during
routine wellness visits—RenalTech delivers a status that indicates
whether or not a cat will develop CKD within the next two years.
Veterinarians can use this information to help pet owners
understand the value of personalized care plans designed to slow
CKD onset and progression by detecting and treating contributing
disease and improving overall feline wellness.
SDMA is a biomarker for kidney function in dogs and cats; it
signals when on average 40% of kidney function is lost versus
creatinine, which increases above reference intervals only when
significant loss of function has occurred, typically up to 75% or
more. IRIS guidelines recommend SDMA to diagnose and stage CKD as
well as monitor disease progression, which allows veterinarians to
match care plans to specific IRIS-recommended care. Antech SDMA
correlates extremely well with existing SDMA tests.* Veterinarians
managing RenalTech positive and RenalTech negative cats can perform
Antech SDMA testing at regular intervals, supporting earlier
disease detection and personalized care plans that tie directly to
IRIS guidelines.
Antech SDMA will be available to customers in late spring. WVC
attendees can learn about Antech's complete feline renal health
portfolio, which includes RenalTech and Antech SDMA, as well as
early care strategies for CKD, by attending the following education
sessions delivered by Dr. Dennis
Chew at The Learning Lounge in the exhibit hall on
Wednesday, February 19:
Taking the Surprise Out of CKD
11:30 AM - 11:55 AM
Initial Management of Stable Chronic Kidney Disease
12:00 PM - 12:25 PM
For more information about RenalTech and recommended care
pathways using the new feline renal health portfolio, please visit
www.antechdiagnostics.com/renaltech. For information about the
science behind RenalTech, please visit Waltham Petcare Science
Institute.
The 92nd Annual WVC Conference takes place from
February 16-19, 2020 at the Mandalay Bay Conference Center in
Las Vegas, Nevada. Visit Antech at
WVC booth #1118.
About Antech
At the heart of Antech is our love for
pets. Combining innovative technologies backed by scientific rigor
with data-driven insights and consultative moments, we help
veterinarians and their teams improve the health and well-being of
the pets we love. Our commitment to customers spans more than 30
years and celebrates their dedication to setting new standards in
pet care quality, which we support through innovative diagnostic,
imaging, education and support services. Today, Antech is driving
the future of pet health as part of Mars Petcare, the world's
leading pet nutrition and health care ecosystem. Visit us
at http://www.antechdiagnostics.com. Follow us on Twitter,
LinkedIn and Facebook.
*Data on file at Antech Diagnostics
View original
content:http://www.prnewswire.com/news-releases/antech-expands-feline-renal-health-portfolio-with-antech-sdma-301005784.html
SOURCE Antech Diagnostics